University of Texas System

Cheng-Yang Wu

Uttam K Tambar

Xiangbing Qi

Wen-Jun Gui

Shih-Chia Tso

Jacinta L Chuang

David T Chuang

R Max Wynn

The present disclosure relates to the identification of PDK inhibitors and their use in the treatment of diseases such as diabetes, cardiovascular disease and cancer. The invention relates to the development of robust PDK inhibitors that can be used to improve glucose metabolism and correct metabolic dysfunction in vivo. Based on the unique structural features present in the ATP-binding pocket of PDK2, a single functional-group change was made in a known Hsp90 inhibitor that binds to the corresponding pocket of the latter protein from the GHKL family. This approach efficiently converted the Hsp90 inhibitor to a highly specific inhibitor for all PDK isoforms. These final PDK inhibitors of this series robustly augments PDC activity with reduced phosphorylation in tissues.

Inhibitors of mitochondrial pyruvate dehydrogenase kinase isoforms 1-4 and uses thereof

Growing community of inventors

Dallas, TX, United States of America

Cheng-Yang Wu